The Official Journal of the Turkish Society Of Clinical Microbiology and Infectious Diseases (KLİMİK)

COVID-19

Filter Newest Oldest Showing 1-20 of 67 results
Original Article / VOLUME 6, ISSUE 2, JUNE 2024

COVID-19 Vaccines and COVID-19 in People Living with HIV

Muhammed Fatih Karaşın and others

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a strain of the coronavirus that causes COVID-19, spread rapidly around the world and was defined as a pandemic on March 12, 2020, by the World Health Organization. As of June 2023, more than 767 million cases were confirmed globally, along with 6.9 million deaths. Read More

Original Article / VOLUME 6, ISSUE 2, JUNE 2024

The COVID-19 Vaccine Hesitancy Among Healthcare Workers: An Exploration of Hesitancy Reasons and Suggestions to Improve Vaccination Rates

Bahar Madran and others

The global impact of the coronavirus disease (COVID-19) pandemic has been profound, affecting billions of lives worldwide. As of June 13, 2024, the virus has infected approximately 704 million people and led to a staggering death toll of 7 million. In the fight against this devastating virus, the development and distribution of COVID-19 vaccines have been identified (...) Read More

Original Article / VOLUME 6, ISSUE 1, MARCH 2024

Individualized High Dose Intravenous Anakinra Treatment in Cancer Patients with COVID-19 Associated Cytokine Storm: A Retrospective Controlled Study

Ramazan Çakmak and Murat Bektaş

Coronavirus disease 2019 (COVID-19) is a potentially life-threatening disease caused by SARS-CoV-2. Clinical findings of COVID-19 are ranged from asymptomatic to severe pneumoniae, acute respiratory distress syndrome, multiorgan failure and death. A severe COVID-19 course is associated with a higher inflammatory state (cytokine storm) due to the excessive release (...) Read More

Original Article / VOLUME 6, ISSUE 1, MARCH 2024

Infection Risk Prediction in Healthcare Settings: Lessons from COVID-19 Contact Tracing

Salih Keskin and others

Contact tracing has been recognized as a critical process in controlling infectious disease epidemics. Its objectives include early identification of potentially infectious cases and prevention of the emergence of new clusters. In the context of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, in-hospital contact-tracing efforts (...) Read More

Brief Report / VOLUME 6, ISSUE 1, MARCH 2024

Comparison of the i-test COVID-19 Rapid Antigen Test with Real-Time Reverse Transcriptase PCR

Muhammet Çağrı Yıldız and others

Polymerase chain reaction (PCR) test is used in high-capacity laboratories in the diagnosis of COVID-19. On the other hand, rapid SARS-CoV-2 antigen tests require less technical expertise and laboratory capacity. Antigen tests, which are faster and cost-effective, are increasingly used in COVID-19 screening and diagnosis. This study aimed to compare the i-test (...) Read More

Original Article / VOLUME 5, ISSUE 4, DECEMBER 2023

Association of Serum Krebs von den Lungen-6 (KL-6) Levels and Disease Severity in Patients Hospitalized with COVID-19

Oğuz Evlice and others

Acute lung injury and sepsis are among the severe clinical outcomes of the coronavirus disease 2019 (COVID-19). Risk factors raise fatality rates, increase the burden on countries’ healthcare facilities, and significantly increase health expenditures due to prolonged inpatient periods. Several studies have revealed a severe illness course in COVID-19 patients, especially in males, older age, and comorbid (...) Read More

Review Article / VOLUME 5, ISSUE 3, SEPTEMBER 2023

COVID-19: An Update on Epidemiology, Prevention and Treatment, September-2023

Serap Şimşek-Yavuz

After the World Health Organization (WHO) declared an end to COVID-19 as a global public health emergency on May 5, 2023, we have entered a new era in the pandemic, and most countries have already returned to normal life. This declaration was resulted from the 12-month downward trend of the pandemic, increased immunity due to the highly effective vaccines, decreased death rates, and decreased pressure on once overwhelmed (...) Read More

Original Article / VOLUME 5, ISSUE 3, SEPTEMBER 2023

Long-Term Symptoms and Quality of Life in Persons with COVID-19

Nuriye Yalçın-Çolak and others

COVID-19, caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), is a zoonotic infection that emerged in Wuhan province of China in December 2019. SARS-COV-2 is a Betacoronavirus that is classified in Riboviria realm, Nidovirales order, and Coronaviridae family (1). Although the fatality rate of SARS-CoV-2 (2.6%) is lower than SARS-CoV (11%) and MERS-CoV (35-50%), it was much more severe worldwide (...) Read More

Brief Report / VOLUME 5, ISSUE 3, SEPTEMBER 2023

B Cell Subtypes in Individuals Received mRNA or Inactivated Vaccine Boosters After Fully Vaccinated with CoronaVac: A Longitudinal Study

Zeynep Ece Kuloğlu and others

In the COVID-19 pandemic, it is essential to estimate the immune responses to various COVID-19 vaccinations to estimate the efficacy of the vaccines. During the ongoing pandemic, different vaccine types and vaccination strategies affect the cellular and molecular elements of innate and adaptive immune systems. Therefore, testing the effectiveness of COVID-19 vaccines in different vaccination (...) Read More

Original Article / VOLUME 5, ISSUE 2, JUNE 2023

Clinical Evaluation of Commercial HARDSON COVID-19 Antigen Rapid Test Kit for Routine COVID-19 Diagnosis

Reza Kamali Kakhki* and others

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a respiratory disease agent belonging to the Betacoronavirus genera. The genome of the virus translates into four major structural proteins, including spike (S), nucleocapsid (N), membrane (M), and envelop (E) proteins. During the pandemic, huge numbers of mutations (...) Read More

Original Article / VOLUME 5, ISSUE 2, JUNE 2023

The Impact of Vaccination Among Hospitalized Patients with the Diagnosis of COVID-19

Yeşim Yıldız and others

Vaccines to prevent SARS-CoV-2 infection are the most promising and effective approach to curb the COVID-19 pandemic, as well as to reduce hospitalizations and prevent mortality.  In our country, the CoronaVac (Sinovac Biotech, China) vaccine started to be administered as of January 13, 2021, and the Comirnaty (BNT162b2, Pfizer-BioNTech) vaccine as (...) Read More

Original Article / VOLUME 5, ISSUE 2, JUNE 2023

COVID-19 Among Patients with Psoriasis: A Single-Center Retrospective Cross-Sectional Study

Özge Kaya and others

Psoriasis, a chronic inflammatory disease, has a multifactorial etiology, including genetic, environmental, and behavioral factors. Since psoriasis is an immune system-mediated disease, immunosuppressive agents and biological treatments are frequently used in its treatment; however, these agents are known to increase the risk of infection. This situation (...) Read More

Original Article / VOLUME 5, ISSUE 1, MARCH 2023

Evaluation of Inflammation-Based Prognostic Risk Scores in Predicting in-Hospital Mortality Risk in COVID-19 Patients: A Cross-Sectional Retrospective Study

Çaşıt Olgun Çelik and others

An acute respiratory syndrome (COVID-19), caused by a novel coronavirus (SARS-CoV-2), has spread from China worldwide and caused a pandemic that brought severe medical, social, and economic problems. The COVID-19 infection results in various clinical presentations ranging from an asymptomatic (...) Read More

Original Article / VOLUME 4, ISSUE 4, DECEMBER 2022

Thyroid Dysfunction among the Patients with Critical COVID-19

Hande Özportakal and others

The world has been fighting against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) for more than two years, leading to more than 605 million cases and 6.4 million deaths as of September 11, 2022. Since the angiotensin-converting enzyme (ACE) is the functional receptor for SARS-CoV-2, predominantly expressed by the alveoli (...) Read More